Your browser doesn't support javascript.
loading
Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning.
Sánchez-Gutiérrez, Teresa; Fernandez-Castilla, Belén; Barbeito, Sara; González-Pinto, Ana; Becerra-García, Juan Antonio; Calvo, Ana.
Afiliación
  • Sánchez-Gutiérrez T; Faculty of Health Science, Universidad Internacional de La Rioja (UNIR), Madrid, Spain.
  • Fernandez-Castilla B; Faculty of Psychology and Educational Sciences, KU Leuven, University of Leuven, Leuven. Belgium.
  • Barbeito S; Faculty of Health Science, Universidad Internacional de La Rioja (UNIR), Madrid, Spain.
  • González-Pinto A; Hospital Universitario de Alava, Servicio de Psiquiatría, BIOARABA, CIBERSAM, Universidad del País Vasco, Leioa, Spain.
  • Becerra-García JA; Faculty of Health Science, Universidad Internacional de La Rioja (UNIR), Madrid, Spain.
  • Calvo A; Faculty of Health Science, Universidad Internacional de La Rioja (UNIR), Madrid, Spain.
Eur Psychiatry ; 63(1): e6, 2020 01 31.
Article en En | MEDLINE | ID: mdl-32093788
BACKGROUND: The implications of cannabis use in the onset of early psychosis and the severity of psychotic symptoms have resulted in a proliferation of studies on this issue. However, few have examined the effects of cannabis use on the cognitive symptoms of psychosis (i.e., neurocognitive functioning) in patients with first-episode psychosis (FEP). This systematic review and meta-analysis aim to assess the neurocognitive functioning of cannabis users (CU) and nonusers (NU) with FEP. METHODS: Of the 110 studies identified through the systematic review of 6 databases, 7 met the inclusion criteria, resulting in 14 independent samples and 78 effect sizes. The total sample included 304 CU with FEP and 369 NU with FEP. The moderator variables were age at first use, duration of use, percentage of males, and age. RESULTS: Effect sizes were not significantly different from zero in any neurocognitive domain when users and NU were compared. Part of the variability in effect sizes was explained by the inclusion of the following moderator variables: (1) frequency of cannabis use (ß = 0.013, F = 7.56, p = 0.017); (2) first-generation antipsychotics (ß = 0.019, F = 34.46, p ≤ 0.001); and (3) country where the study was carried out (ß = 0.266, t = 2.06, p = 0.043). CONCLUSIONS: This meta-analysis indicates that cannabis use is not generally associated with neurocognitive functioning in patients with FEP. However, it highlights the deleterious effect of low doses of cannabis in some patients. It also stresses the importance of the type of antipsychotic prescription and cannabis dose as moderator variables in the neurocognitive functioning of CU with FEP.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Psicóticos / Cannabis / Pruebas de Estado Mental y Demencia Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Eur Psychiatry Asunto de la revista: PSIQUIATRIA Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Psicóticos / Cannabis / Pruebas de Estado Mental y Demencia Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Eur Psychiatry Asunto de la revista: PSIQUIATRIA Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido